- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05648396
Japan FFRangio Clinical Outcomes Study
Japan Multicentre FFRangio Outcomes Registry
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background:
Visual assessment of the severity of coronary stenosis is known to have a poor diagnostic accuracy for identifying functionally significant lesion [1,2). The fractional flow reserve (FFR) is an index that quantifies the hemodynamic impact of a stenosis in an epicardial coronary artery. It is defined as the ratio of hyperemic myocardial flow in the presence of stenosis to the hyperemic flow in its absence, and is obtained by measuring the distal coronary pressure and the aortic pressure, respectively, using a pressure-measuring guidewire during maximal hyperemia [2,3]. Clinical outcome studies have shown that medical therapy should be preferred for non-hemodynamically significant lesions (FFR>0.80), and coronary revascularization should be considered in cases of significant functional stenosis (FFR≤0.80) [4-11]. Accordingly, both American and European revascularization guidelines recommend using FFR to guide coronary revascularization, especially in stable coronary artery disease patients [12,13]. In spite of these recommendations, the utilization of FFR in clinical practice remains low [14]. Recently, methods to calculate angiogram based FFR (abFFR) (without the need for pressure wires or induction of maximal coronary hyperemia) have become available. A meta-analysis of 14 studies examining various abFFR technologies ( total of 1,842 lesions), reported a sensitivity of 89%, specificity of 90%, and a C-statistic of 0.84 compared to wire based FFR (wbFFR) [15], highlighting the potential for abFFR technologies to facilitate the integration of physiologic assessment into daily cathlab practice. The FFRangioTM system (CathWorks, Kfar-Saba, Israel; Figure 1), is an angiogram-derived FFR technology that has shown excellent diagnostic performance (overall accuracy 92.6%) when compared to wire based FFR in a large pooled cohort of individual patients data from 5 individual studies (588 patients, 700 lesions) [16]. FFRangio has already received FDA 510(k) clearance for clinical use as a stand-alone technology without the need for concurrent wire based FFR measurement [17]. FFRangio has been in clinical use in Japan since 2019, but there is very limited data on the clinical outcomes of FFRangio guided treatment.
Recently, the first study examining the outcomes of FFRangio guided treatment for patients undergoing angiography for suspected coronary artery disease has reported excellent 1 year results for both FFRangio guided revascularization as well as deferral [18], but more data is needed to more appropriately assess the technology in real world patients.
The aim of this multicenter registry is to expand the evidence base on outcomes of FFRangio guided treatment for coronary artery disease, focusing on outcomes of Japanese patients.
Methods:
A retrospective, multicenter registry of consecutive patients in whom FFRangio is used to assess the physiologic significance of at least 1 coronary lesion and guide the treatment decisions .
Inclusion criteria:
• Patients undergoing coronary angiogram for a clinical indication, for whom FFRangio is used to assess the physiologic significance of at least 1 coronary lesion and guide the treatment decisions.
Exclusion criteria:
- Culprit lesion of a STEMI (patients undergoing PCI for non-culprit lesions can be included if the culprit lesion has been successfully treated prior to the non-culprit PCI
- Presence of significant (moderate+) valvular heart disease
- Chronic total occlusion in one of the coronary arteries
- Isolated significant left main disease
- Prior coronary artery bypass graft surgery
- Clinical presentation of cardiogenic shock or severe LV dysfunction
- Coronary anomalies
Endpoints
Primary endpoint:
• composite of all cause death/myocardial infarction(MI)/repeat revascularization(RR) at 1 year follow up.
Secondary endpoints:
- The individual components of the primary endpoint
- Cardiovascular (CV) death
- Urgent RR (performed as an inpatient during an admission for ACS).
- Target vessel RR
- Target lesion RR
- Target vessel MI
- Target lesion MI
Timing of follow up:
Six and 12 months post procedure (primary analysis will include 1 year data) and yearly follow up thereafter up to 5 years.
Ascertainment and adjudications of clinical events The clinical endpoints events will be identified by the participating centres through the patients' electronic medical record and will be further verified, when possible, by interviews conducted during in person/virtual outpatient clinic visits and/or telephone follow up.
Sample size Our aim is to include up to 10 high volume FFRangio centres from Japan and Israel with a goal of reaching a sample size of at least 1,500 patients.
Ethical aspects The study will be approved by the local institutional review boards at each participating centre. Since there is no intervention in the clinical care given to the patient, waiver of the need for patient's informed consent will besought from the IRB/EC.
If participating investigators come by patients' personal information ( information on living individuals that can be used to specific individuals by name, date of birth or other description), such information shall be treated and protected under strict confidentiality. Further more participating investigators shall conduct this research in accordance with ethical principles on the Declaration of Helsinki.
Expected time frame Initiation of registry: Q4 2022 Expected data collection for 1,500 patients: Q2 2023 Initial data analysis: Q3 2023 (median follow up of 6 months for a sample size of 1,500 patients )
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Petah tikva, Israel, 4941492
- Rabin Medical Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria:
• Patients undergoing coronary angiogram for a clinical indication, for whom FFRangio is used to assess the physiologic significance of at least 1 coronary lesion and guide the treatment decisions.
Exclusion criteria:
- Culprit lesion of a STEMI (patients undergoing PCI for non-culprit lesions can be included if the culprit lesion has been successfully treated prior to the non-culprit PCI
- Presence of significant (moderate+) valvular heart disease
- Chronic total occlusion in one of the coronary arteries
- Isolated significant left main disease
- Prior coronary artery bypass graft surgery
- Clinical presentation of cardiogenic shock or severe LV dysfunction
- Coronary anomalies
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Other
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Revascularization
Patients undergoing angiogram in which FFRangio is used to assess the physiologic significance of at least one coronary lesion, and based on this assessment are referred for coronary revascularization (PCI/CABG).
|
Assessing the physiologic significance of an intermediate coronary lesion/lesions using FFRangio - a non invasive method to calculate the fractional flow reserve (FFR) of the assessed lesion.
|
Deferral
Patients undergoing angiogram in which FFRangio is used to assess the physiologic significance of at least one coronary lesion, and based on this assessment are assigned to conservative management (optimal guidelines directed medical treatment).
|
Assessing the physiologic significance of an intermediate coronary lesion/lesions using FFRangio - a non invasive method to calculate the fractional flow reserve (FFR) of the assessed lesion.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
composite of Cardio-Vascular(CV) mortality/Myocardial infarction (MI)/Repeat revascularization
Time Frame: 1 year
|
Composite of CV mortality/MI/Repeat revascularization
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall death
Time Frame: 1 year
|
Death due to any cause
|
1 year
|
Cardio Vascular death
Time Frame: 1 year
|
Death due to a Cardiovascular cause
|
1 year
|
MyocardiaI infarction (MI)
Time Frame: 1 year
|
Defined by the universal definition of MI
|
1 year
|
Repeat revascularization
Time Frame: 1 year
|
Any revascularization procedure
|
1 year
|
Urgent repeat revascularization
Time Frame: 1 year
|
Any revascularization procedure performed urgently (i.e as an inpatient with an indication of acute coronary syndrome)
|
1 year
|
target vessel repeat revascularization
Time Frame: 1 year
|
Any revascularization procedure involving the target vessel assessed during the index procedure
|
1 year
|
Target lesion repeat revascularization
Time Frame: 1 year
|
Any revascularization procedure involving the target lesion assessed during the index procedure
|
1 year
|
Target vessel MI
Time Frame: 1 year
|
Any MI related to target vessel assessed during the index procedure
|
1 year
|
Target lesion MI
Time Frame: 1 year
|
Any MI related to target lesion assessed during the index procedure
|
1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Guy Witberg, MD, MPH, Rabin Medical Centre
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RMC-12-2022
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on FFRangio
-
CathWorks Ltd.CRFCompletedCoronary Artery DiseaseIsrael, United States, Belgium, Denmark
-
CathWorks Ltd.CompletedMulti Vessel Coronary Artery DiseaseJapan
-
Centre Hospitalier Universitaire VaudoisUnknownAcute Coronary SyndromeSwitzerland
-
CathWorks Ltd.Cardiovascular Research Foundation, New YorkRecruitingPercutaneous Coronary InterventionUnited States, Israel